No price history available.
Key financial summary
Financials in BRL| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | BRLm | 14,029 | 20,382 | 22,987 | 46,509 | 50,571 | 55,726 | N/A | N/A |
| Operating profit | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | BRLm | 428 | 1,575 | 1,195 | 2,041 | 3,847 | 4,688 | N/A | N/A |
| EPS reported | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in BRL| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Rede D'Or São Luiz S.A. manages an extensive healthcare network across Brazil. The company delivers a comprehensive range of medical services, covering areas such as neurology, oncology, and pathology, alongside specialized treatments for hemangioma, lymphangioma, lymphatic malformation, and various vascular anomalies and tumors. Its offerings also include advanced vascular surgery, radiology, and interventional radiology. For younger patients, it provides expert care in pediatric cardiology, oncology, hematology, and surgery. This extensive enterprise comprises 51 wholly-owned hospitals, one managed hospital, and 47 oncology clinics, housing a total of 9,000 beds. Complementary services like blood banks, dialysis centers, and diverse specialized outpatient clinics are also part of its portfolio. Notably, Rede D'Or is equipped with robot surgery facilities across Brazil. Its geographical footprint extends to the states of Rio de Janeiro, São Paulo, Pernambuco, Bahia, Maranhão, Sergipe, Ceará, Paraná, and the Federal District. Founded in 1977, with its headquarters in São Paulo, Brazil, the company was previously known as Hospital Maternidade São Luiz S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rede D'Or São Luiz S.A. (RDOR3.SA)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Rede D'Or São Luiz S.A. manages an extensive healthcare network across Brazil. The company delivers a comprehensive range of medical services, covering areas such as neurology, oncology, and pathology, alongside specialized treatments for hemangioma, lymphangioma, lymphatic malformation, and various vascular anomalies and tumors. Its offerings also include advanced vascular surgery, radiology, and interventional radiology. For younger patients, it provides expert care in pediatric cardiology, oncology, hematology, and surgery. This extensive enterprise comprises 51 wholly-owned hospitals, one managed hospital, and 47 oncology clinics, housing a total of 9,000 beds. Complementary services like blood banks, dialysis centers, and diverse specialized outpatient clinics are also part of its portfolio. Notably, Rede D'Or is equipped with robot surgery facilities across Brazil. Its geographical footprint extends to the states of Rio de Janeiro, São Paulo, Pernambuco, Bahia, Maranhão, Sergipe, Ceará, Paraná, and the Federal District. Founded in 1977, with its headquarters in São Paulo, Brazil, the company was previously known as Hospital Maternidade São Luiz S.A.